Nichaela Harbison-Price

Nichaela Harbison-Price

Auto-generated profile, based on publicly available information

Nichaela Harbison-Price

Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
SBStephan Brouwer
Stephan Brouwer
TRTania Rivera-Hernandez
Tania Rivera-Hernandez
BCBodie F. Curren
Bodie F. Curren
NHNichaela Harbison-Price
Nichaela Harbison-Price
DODavid Manuel Pereira De Oliveira
David Manuel Pereira De Oliveira
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker

24 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MDMark Davies
Mark Davies
NKNadia Keller
Nadia Keller
SBStephan Brouwer
Stephan Brouwer
MJMagnus G. Jespersen
Magnus G. Jespersen
ACAmanda J. Cork
Amanda J. Cork
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
A new variant of Streptococcus pyogenes serotype M1 (designated ‘M1UK’) has been reported in the United Kingdom, linked with seasonal scarlet fever surges, marked increase in invasive infections, and exhibiting enhanced expression of the superantigen SpeA. The progenitor S. pyogenes ‘M1global’ and M1UK clones can be differentiated by 27 SNPs and 4 indels, yet the mechanism for speA upregulation is unknown. Here we investigate the previously unappreciated expansion of M1UK in Australia, now isolated from the majority of serious infections caused by serotype M1 S. pyogenes. M1UK sub-lineages circulating in Australia also contain a novel toxin repertoire associated with epidemic scarlet fever causing S. pyogenes in Asia. A single SNP in the 5’ transcriptional leader sequence of the transfer-messenger RNA gene ssrA drives enhanced SpeA superantigen expression as a result of ssrA terminator read-through in the M1UK lineage. This represents a previously unappreciated mechanism of toxin expression and urges enhanced international surveillance.

18 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAndre Mu
Andre Mu
WKWilliam P. Klare
William P. Klare
SBSarah L Baines
Sarah L Baines
CPC. N. Ignatius Pang
C. N. Ignatius Pang
RGRomain Guérillot
Romain Guérillot
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
Even in the setting of optimal resuscitation in high-income countries severe sepsis and septic shock have a mortality of 20–40%, with antibiotic resistance dramatically increasing this mortality risk. To develop a reference dataset enabling the identification of common bacterial targets for therapeutic intervention, we applied a standardized genomic, transcriptomic, proteomic and metabolomic technological framework to multiple clinical isolates of four sepsis-causing pathogens: Escherichia coli, Klebsiella pneumoniae species complex, Staphylococcus aureus and Streptococcus pyogenes. Exposure to human serum generated a sepsis molecular signature containing global increases in fatty acid and lipid biosynthesis and metabolism, consistent with cell envelope remodelling and nutrient adaptation for osmoprotection. In addition, acquisition of cholesterol was identified across the bacterial species. This detailed reference dataset has been established as an open resource to support discovery and translational research.

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NHNichaela Harbison-Price
Nichaela Harbison-Price
ISIsmail Sebina
Ismail Sebina
RBRhiannon A. Bolton
Rhiannon A. Bolton
MFMeredith Finn
Meredith Finn
ACAmanda J. Cork
Amanda J. Cork
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
A commercial vaccine to address the high global burden of Group A Streptococcus (GAS) disease is an urgent and unmet medical need. Messenger RNA (mRNA) lipid-nanoparticle (LNP) vaccines represent a largely untapped platform for targeting bacterial pathogens. Here, we evaluate the immunogenicity and preclinical efficacy of a multicomponent mRNA-LNP vaccine formulation based on the GAS vaccine, Combo#5. Combo#5 mRNA-LNP antigens confer protection from infection in mouse intraperitoneal and subcutaneous challenge models. Combo#5 mRNA-LNP vaccination generates significantly increased frequencies and numbers of effector type CD4+ and CD8 + T cells in the spleen, enhances T follicular helper cells, germinal center B cells and memory B cells in the spleen and draining lymph nodes, and boosts the production of antigen-specific antibodies. These findings demonstrate the potential of the mRNA-LNP platform for the development of vaccines against bacterial pathogens.

3 July 2023 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
SBStephan Brouwer
Stephan Brouwer
TRTania Rivera-Hernandez
Tania Rivera-Hernandez
BCBodie F. Curren
Bodie F. Curren
NHNichaela Harbison-Price
Nichaela Harbison-Price
DODavid Manuel Pereira De Oliveira
David Manuel Pereira De Oliveira
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker

2 July 2026 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
BPBrody Pullinger
Brody Pullinger
NHNichaela Harbison-Price
Nichaela Harbison-Price
ISIsmail Sebina
Ismail Sebina
JNJack Na
Jack Na
GBGabrielle T. Belz
Gabrielle T. Belz
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
SUMMARY: The messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine platform is the newest tool in the vaccination arsenal for combating infectious diseases, rare genetic diseases, and cancer. Since 2020, major advances in preclinical and clinical studies have demonstrated the efficacy of mRNA-LNP vaccines against viral pathogens and in cancer. However, studies investigating the efficacy of mRNA-LNP vaccines against bacterial pathogens remain sparse due to substantial bacterial vaccine-specific challenges. Here, we highlight key challenges impeding the development of mRNA-LNP vaccines against human bacterial pathogens, the advantages that can be gained by utilizing the mRNA-LNP platform for bacterial vaccines, and progress toward the development of mRNA-LNP vaccines against bacterial infections.